Publications

Add filters (0)

381 results

Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease.

April 1, 2026

Gastroenterology

Abstract BACKGROUND & AIMS Alcohol is a key driver of liver-related mortality, and phosphatidylethanol (PEth) is a direct biomarker of alcohol intake. We investigated the prognostic performance of PEth with noninvasive liver fibrosis tests (NITs) for predicting hepatic decompensation in an alcohol-related liver disease (ALD) at-risk population. METHODS Prospective cohort study with 411 at risk […]

Read publication

A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

April 1, 2026

J Gastroenterol Hepatol

Abstract BACKGROUND Noninvasive fibrosis testing is crucial for metabolic dysfunction-associated steatotic liver disease (MASLD) management. This study evaluated a marker of activated mesenchymal fibrogenic cells, circulating fibroblast activation protein (cFAP), in a novel diagnostic algorithm, FAP Index, for patients with MASLD. METHODS Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n = 160) […]

Read publication

Characterization of a novel assay for full-length endotrophin in heart failure with preserved ejection fraction.

March 18, 2026

Sci Rep

Abstract Endotrophin is a matrikine released from the C-terminus of the alpha-3 chain of type VI collagen, gaining increasing attention both as a biomarker and as a therapeutic target in the cardiometabolic space. So far, it has been quantified in circulation by the PRO-C6 assay, which detects different-sized proteolytic fragments of the C-terminus, including endotrophin. […]

Read publication

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.

March 1, 2026

Aliment Pharmacol Ther

Abstract BACKGROUND Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complications. METHODS Patients with stable ACLD (n = 232) undergoing hepatic venous pressure gradient (HVPG) measurement were included. Blood biomarkers reflecting fibrosis formation (PRO-C3, PRO-C6, PRO-C4 and PRO-C18L) […]

Read publication

Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions.

February 1, 2026

Am J Physiol Cell Physiol

Abstract Endotrophin, a biologically active fragment derived from the α3 chain of collagen type VI, has emerged as both a risk biomarker and a potential pathogenic factor in cardiovascular-kidney-metabolic (CKM) syndrome. Over the past decade, research has shed light on its role in various noncommunicable diseases, emphasizing its signaling properties and diagnostic potential. Despite these […]

Read publication

Cytokine profiling of molecular endotypes of knee osteoarthritis: insights from the IMI-APPROACH cohort.

January 27, 2026

Arthritis Res Ther

Abstract BACKGROUND: Molecular endotypes that decipher the heterogeneity of osteoarthritis (OA) have been described. This exploratory study aimed to further the molecular understanding of three previously identified biomarker-based endotypes of knee OA through cytokine profiling. METHODS: Fifteen pro- and anti-inflammatory cytokines were measured in serum at the six-, 12-, and 24-month follow-up visits of 277 […]

Read publication

Identification of novel plasma proteomic biomarkers of Dupuytren disease.

January 1, 2026

PLoS One

Abstract Dupuytren Disease (DD) is a chronic progressive disease that can cause disabling hand deformities. The most common treatments have either high complication rates or high early recurrence rates. Dupuytren lacks a staging biomarker profile to inform the development of preventive therapeutics to improve long-term outcomes. This multi-omic study aimed to create a DD blood […]

Read publication

Discovery and Clinical Validation of C1M and C4M as Soluble Biomarkers for Diagnosis, Prognosis, and Symptom Prediction in Psoriatic Disease and Other Inflammatory Arthropathies.

December 1, 2025

J Rheumatol

Abstract Psoriatic disease (PsD) is a complex, heterogeneous disease with unmet medical needs in terms of its diagnosis, management, and prognosis. The identification of biomarkers could improve the implementation of precision medicine in PsD, but to date, none of these biomarkers have been clinically validated. Biomarkers can support clinical trials in several ways, including (1) […]

Read publication

Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts.

November 14, 2025

Thorax

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV collagen (COL4) in the BM changes with the progression of IPF. METHODS COL4 synthesis (PRO-C4) was detected in blood by the nordicPRO-C4 biomarker in patients with […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication